The House Passes a New Act Which Will Accelerate Research for ALS and Related Diseases
source: pixabay.com

The House Passes a New Act Which Will Accelerate Research for ALS and Related Diseases

Three organizations focused on amytrophic lateral sclerosis (ALS) as well as other rare neurodegenerative diseases, have just celebrated the House of Representatives' passage of the ACT for ALS (H.R.3537/S.1813). The…

Continue Reading The House Passes a New Act Which Will Accelerate Research for ALS and Related Diseases

Study of the Week: Study Reveals a Key Mechanism of Neurodegenerative Diseases

Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…

Continue Reading Study of the Week: Study Reveals a Key Mechanism of Neurodegenerative Diseases
Newly FDA Approved Ketamine Has the Potential to Slow ALS Progression
qimono / Pixabay

Newly FDA Approved Ketamine Has the Potential to Slow ALS Progression

An October 2021 report published in the Globe and Newswire carried an announcement by Fabio Chianelli, CEO of the biotech company PharmaTher Holdings. The FDA approved orphan drug status for…

Continue Reading Newly FDA Approved Ketamine Has the Potential to Slow ALS Progression
Is There a Right or Wrong in the Debate Between Patients and Manufacturers to Release Drugs Through Compassionate Use?
source: pixabay.com

Is There a Right or Wrong in the Debate Between Patients and Manufacturers to Release Drugs Through Compassionate Use?

  Following several Patient Worthy articles on the subject earlier this year, Fierce Biotech recently published news that Biogen is preparing to release the Phase III VALOR trial drug, tofersen,…

Continue Reading Is There a Right or Wrong in the Debate Between Patients and Manufacturers to Release Drugs Through Compassionate Use?
New Hope for ALS and Friedreich’s Ataxia Patients Through Viral Vector Transports
mcmurryjulie / Pixabay

New Hope for ALS and Friedreich’s Ataxia Patients Through Viral Vector Transports

A recent announcement in Biospace by Capsida Biotherapeutics and CRISPR Therapeutics of their newly-formed partnership offers renewed hope for amyotrophic lateral sclerosis (ALS) and Friedreich’s Ataxia patients. The companies believe…

Continue Reading New Hope for ALS and Friedreich’s Ataxia Patients Through Viral Vector Transports
Masitinib Studies Suspended Over Ischemic Heart Disease Risk
https://pixabay.com/en/anatomy-human-heart-pulse-frequency-2328534/

Masitinib Studies Suspended Over Ischemic Heart Disease Risk

Altogether, AB Science has been evaluating a tyrosine kinase inhibitor, masitinib, for a variety of conditions including amyotrophic lateral sclerosis (ALS), COVID-19, and mastocytosis. But according to ALS News Today,…

Continue Reading Masitinib Studies Suspended Over Ischemic Heart Disease Risk